Resolution to amend the Articles of Association

The meeting resolved, in accordance with the Board’s proposal, to amend the provisions of the Articles of Association regarding limits on share capital and the number of shares. The Board of Directors has prepared three alternative proposals for amendments to the Articles of Association—Alternative A, Alternative B, and Alternative C—with the aim of enabling the rights offering of shares proposed to be authorized under item 8 on the agenda. Only one set of Articles of Association is intended to be registered with the Swedish Companies Registration Office. Which set of Articles of Association is ultimately registered depends on the final transaction structure and the number of shares issued, subscribed for, and paid for in the rights issue.

The amendments entail the following new limits for the share capital and the number of shares:

Option A: The share capital shall be no less than SEK 4,964,000 and no more than SEK 19,856,000. The number of shares shall be no less than 58,400,000 and no more than 233,600,000.

Option B: The share capital shall be no less than SEK 9,928,000 and no more than SEK 39,712,000. The number of shares shall be no less than 116,800,000 and no more than 467,200,000.

Option C: The share capital shall be no less than SEK 19,856,000 and no more than SEK 79,424,000. The number of shares shall be no less than 233,600,000 and no more than 934,400,000.

The meeting authorized the Board of Directors to determine which of the alternatives shall ultimately be filed for registration with the Swedish Companies Registration Office, based on what the Board, after considering the final terms and the outcome of the rights issue, deems most appropriate. The Board may also deem it most appropriate not to register any amendment to the Articles of Association at all.

The resolution to amend the Articles of Association is conditional upon the Extraordinary General Meeting also resolving to approve the authorization in accordance with the Board’s proposal under item 8 on the agenda.

Resolution on authorizing the Board of Directors to decide on issuances

The meeting resolved, in accordance with the Board’s proposal, to authorize the Board, during the period until the next Annual General Meeting, on one or more occasions, to decide on the issuance of shares, convertibles, and/or warrants entitling the holder to subscribe for, or involving the issuance of, a maximum number of shares within the limits of the Articles of Association in force at any given time, with or without deviation from the shareholders’ preferential subscription rights. The authorization may be exercised on one or more occasions, and the Board of Directors shall have the right to decide on the detailed terms of the issue on each individual occasion. In addition to cash payment, payment may also be made with non-cash consideration or by set-off, or otherwise subject to conditions.

To ensure that the Company’s current shareholders are not disadvantaged relative to any external investor(s) who may subscribe for shares in the Company, the Board deems it appropriate that an issuance with deviation from shareholders’ preferential subscription rights be made at the Board’s market-based assessed subscription price, subject to a market-based issue discount where applicable.

The Board of Directors, or a person appointed by the Board, is authorized to make any minor adjustments to the resolutions of the Extraordinary General Meeting that may prove necessary in connection with registration with the Swedish Companies Registration Office.

Complete documents regarding the Extraordinary General Meeting are available on BiBBInstruments’ website, www.bibbinstruments.com.

This is a translation of the Swedish press release. If there should be any discrepancies, the Swedish language version prevails.

For more information about BiBB, please contact:
Fredrik Lindblad, CEO
E-mail: fredrik.lindblad@bibbinstruments.com
Phone: +46 70 899 94 86
www.bibbinstruments.com

About BiBB

BiBBInstruments AB is a cancer diagnostics company that develops and commercializes EndoDrill®, the world’s first series of powered endoscopic biopsy instruments with market clearance in the United States and CE marking in Europe. EndoDrill® is designed to collect core tissue samples (core needle biopsies, CNB) with high diagnostic accuracy and aims to improve the diagnosis of cancer in, among others, the stomach, pancreas, liver, lungs and urinary bladder. The product portfolio targets the global market for ultrasound-guided endoscopic biopsy instruments (EUS/EBUS), one of the most advanced and fastest-growing segments in modern endoscopy. BiBB received market clearance (510(k)) from the U.S. Food and Drug Administration (FDA) for its first instrument, EndoDrill® GI, in 2023 and obtained CE marking under the EU Medical Device Regulation (MDR) in 2024 for all three product variants: EndoDrill® GI, EndoDrill® EBUS and EndoDrill® URO. The U.S. launch of EndoDrill® GI was initiated in the autumn of 2025 in collaboration with TaeWoong Medical USA. The EndoDrill® system consists of sterile single-use instruments and a proprietary drive system. BiBB was founded in 2013 by Dr Charles Walther, a cancer researcher at Lund University and a senior consultant in clinical pathology at Skåne University Hospital. The company is headquartered at Medicon Village in Lund, Sweden, and its shares are traded on Spotlight Stock Market (ticker: BIBB).